top of page

Rethinking hair-loss treatment from the scalp up.

aevX Bio PLGA microsphere technology for androgenetic alopecia
Hair-loss treatment still asks too much of patients.

aevX Bio is a Swiss biotechnology company developing long-acting treatments delivered directly to the scalp, designed to reduce the risk of systemic side effects, lift the burden of daily treatment and change what patients have to accept to treat hair loss – including women who have too often been excluded from effective treatment options.

Hair loss is common. Its impact is anything but superficial.

Gradient

Available Therapies
fall short

Oral Finasteride
Oral Finasteride_edited_edited.png

Strong efficacy but associated with systemic exposure and tolerability concerns. Not indicated for women.

Topical Therapies
Minoxidil (topical)_edited.png

Require continuous daily administration and may still result in systemic leakage.

Hair transplantation
Hair transplatation.png

Invasive, costly and limited by donor hair availability.

Why It Matters

50% of men experience androgenetic alopecia by age 50.

40% of women experience androgenetic alopecia by age 50.

Today’s treatment options still force trade-offs between efficacy, convenience and systemic safety.

The aevX Solution

Local Therapy. Sustained Delivery. Designed for Systemic Safety.

Lead candidate: AV^2

AV^2 is being developed to address one of the central limitations of current androgenetic alopecia treatments: the challenge of delivering effective local activity without unwanted systemic exposure.

Built on expertise

Founder-led development from therapeutic innovation through execution

Clinical expertise spanning dermatology, endocrinology and aesthetic medicine

Regulatory and IP expertise embedded from the outset

Deep industry relationships across biotech, pharma, and clinical development

We welcome conversations with investors, pharmaceutical partners, dermatology experts, CDMOs, translational research organisations and clinical development partners.

Scroll right

Industry Voices.
Expert perspectives on the aevX Bio approach.

A.Meier.png

"The clinical rationale is compelling: modulate androgen activity where it matters, in the scalp, while avoiding unnecessary systemic DHT suppression."

Christoph A. Meier, Prof. Dr. med.

FMH in Endocrinology and Diabetology, FMH in General Internal Medicine

o.Messerli.png

“If local delivery can preserve finasteride-level efficacy while minimising systemic exposure, I would expect strong interest from both male and female patients, and I would be highly inclined to offer it in my practice.”

Olivia Messerli-Odermatt, Dr. med.

FMH Dermatology & Venereology

C.George.png

“The concept fits a clear clinical gap: patients want visible results, but many do not want a daily lifelong medication or the perceived risks of systemic hormone modulation.”

Cédric A. George, Dr. med.

FMH in Plastic, Reconstructive & Aesthetic Surgery

a.Rey.png

“Same efficacy as finasteride, without the systemic exposure? I'd offer it in my practice tomorrow.”

Alexandre Rey, Dr. med.

FMH in Endocrinology and Diabetology

bottom of page